More focused study.
The trial of the vaccine, produced by the Vaccine Research Center at the National Institute of Infectious and Allergy Disease, had been planned to include 2,400 men in the usa in a scholarly study called PAVE 100. However, the company said that it decided that the vaccine did not warrant a trial of this size and scope. Rather NIAID said it’ll plan a smaller, more focused medical trial made to see whether the product has a significant effect on the quantity of virus in a person’s blood. If an impact is found, then additional studies, or an growth of the analysis could be carried out. NIAID stated it acted after reviewing the full total results of the Stage trial, a study of another vaccine that was halted last fall after reports of an increased number of infections among volunteers getting involved in the test. (more…)